PRISM Weight Loss Index Leader LEXX Soars 24% on Positive DehydraTECH-Processed Rybelsus® Study Results
    PRISM Weight Loss Index Leader LEXX Soars 24% on Positive DehydraTECH-Processed Rybelsus® Study Results
    PRISM Biotech

    August 30, 2024 - by Editor Prism MarketView

    PRISM Weight Loss Index Leader LEXX Soars 24% on Positive DehydraTECH-Processed Rybelsus® Study Results

    30 August 2024

    New York, August 30, 2024 - PRISM MarketView - Lexaria Bioscience Corp. (NASDAQ: LEXX), today’s standout in the PRISM Weight Loss Index, saw its shares surge 24% following the announcement of promising results from its second human pilot study, GLP-1-H24-2. The study highlighted the benefits of DehydraTECH-processed Rybelsus® capsules, designed to enhance the delivery of the GLP-1 drug semaglutide.
    Lexaria Bioscience - Prism MarketView

    Lexaria Bioscience - Prism MarketView

    Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream t

    Read More

    Key Highlights:
    • No Adverse Events: None of the nine participants who took the DehydraTECH-processed Rybelsus® capsules experienced any adverse events, compared to six out of nine participants who reported mild adverse events with standard Rybelsus® tablets.
    • Improved Tolerability: The study confirmed that DehydraTECH-processed Rybelsus® capsules were better tolerated than commercially available Rybelsus® tablets, which are associated with gastrointestinal issues like nausea and diarrhea.
    • Innovative Delivery Methods: The study also tested a new in-mouth dissolvable tablet format for DehydraTECH-processed Rybelsus®, which showed promise in delivering the drug through sublingual and buccal absorption.
    Recent findings from the same study indicated a trend toward higher overall absorption of semaglutide under fed conditions with DehydraTECH-processed Rybelsus® capsules, despite the usual reduction in absorption with food. Lexaria continues to advance its 2024 GLP-1 experimental program, including the finalization of an ongoing animal study and preparations for an upcoming 12-week chronic human study focused on fasted dosing conditions.
    About PRISM MarketView:
    Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
    To see this content properly accept cookies.
    Disclaimer:
    PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    Prism MarketView | Stock Market News & Investment Opportunities
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.